We need to mandate drug cost transparency on electronic medical records.
作者信息
Gorfinkel Iris, Lexchin Joel
机构信息
PrimeHealth Clinical Research - Family Practice (Gorfinkel); School of Health Policy and Management (Lexchin), Faculty of Health, York University, Toronto, Ont.
出版信息
CMAJ. 2017 Dec 18;189(50):E1541-E1542. doi: 10.1503/cmaj.171070.
Abstract
摘要
相似文献
1
We need to mandate drug cost transparency on electronic medical records.我们需要强制要求电子病历上的药品成本透明度。
CMAJ. 2017 Dec 18;189(50):E1541-E1542. doi: 10.1503/cmaj.171070.
2
Measuring EHR pain points: high cost, poor functionality outweigh benefits, ease of access.衡量电子健康记录（EHR）的痛点：高成本、功能差超过了其优势以及易于获取的特点。
Med Econ. 2014 Feb 10;91(3):28, 30.
3
Exploring the remote release of information.
J AHIMA. 2012 Oct;83(10):56-8.
4
Costs, control, data access remain top EHR concerns. Interview by Lois A Bowers.
Med Econ. 2013 Jan 25;90(2):56, 59.
5
National electronic health records initiative remains muddled, auditors say.审计人员称，国家电子健康记录计划仍一片混乱。
CMAJ. 2010 Jun 15;182(9):E383-4. doi: 10.1503/cmaj.109-3242. Epub 2010 Apr 26.
6
[Optimizing the nursing process and establishing transparency].优化护理流程并建立透明度
Krankenpfl Soins Infirm. 2013;106(12):28-9.
7
Adoption of electronic health records in UK hospitals: lessons from the USA.英国医院采用电子健康记录：来自美国的经验教训。
Lancet. 2014 Jul 5;384(9937):8-9. doi: 10.1016/S0140-6736(14)61099-0.
8
As funds to sync health records dwindle, research could suffer.
Nat Med. 2014 Nov;20(11):1225-6. doi: 10.1038/nm1114-1225.
9
Some provinces still delay access to health records via patient portals.一些省份仍在拖延通过患者门户网站获取健康记录。
CMAJ. 2019 Dec 2;191(48):E1341. doi: 10.1503/cmaj.1095829.
10
Assessing the cost of electronic health records: a review of cost indicators.评估电子健康记录的成本：成本指标综述。
Telemed J E Health. 2010 Nov;16(9):963-72. doi: 10.1089/tmj.2010.0014. Epub 2010 Oct 19.
引用本文的文献
1
Where Do Real-Time Prescription Benefit Tools Fit in the Landscape of High US Prescription Medication Costs? A Narrative Review.美国高处方药费用背景下，实时处方效益工具的定位如何？一篇叙述性综述。
J Gen Intern Med. 2023 Mar;38(4):1038-1045. doi: 10.1007/s11606-022-07945-z. Epub 2022 Nov 28.
2
Does price disclosure in pharmaceutical advertising result in price transparency? Evidence from a randomized experiment.药品广告中的价格披露能否带来价格透明度？来自一项随机实验的证据。
Explor Res Clin Soc Pharm. 2022 Sep 19;8:100180. doi: 10.1016/j.rcsop.2022.100180. eCollection 2022 Dec.
3
Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy.迈向大数据、人工智能与医院药学之间的共生关系。
J Pharm Policy Pract. 2020 Nov 9;13(1):75. doi: 10.1186/s40545-020-00276-6.
4
[Not Available].[无可用内容]
Can Fam Physician. 2020 Oct;66(10):e251-e254.
5
Engaging physicians to prescribe more cost-effectively: Blueprint for change.促使医生更经济高效地开处方：变革蓝图。
Can Fam Physician. 2020 Oct;66(10):723-725.
6
Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study.加拿大慢性乙型肝炎抗病毒治疗的可及性差异：一项描述性研究。
CMAJ Open. 2019 Mar 29;7(1):E182-E189. doi: 10.9778/cmajo.20180108. Print 2019 Jan-Mar.
7
Effectiveness of provider price display in computerized physician order entry (CPOE) on healthcare quality: a systematic review.在计算机化医师医嘱录入 (CPOE) 中展示医疗服务提供者价格对医疗质量的影响：系统评价。
J Am Med Inform Assoc. 2018 Sep 1;25(9):1228-1239. doi: 10.1093/jamia/ocy076.
8
The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey.加拿大处方药患者付费的后果：一项横断面调查。
CMAJ Open. 2018 Feb 5;6(1):E63-E70. doi: 10.9778/cmajo.20180008.
本文引用的文献
1
Out-of-pocket costs and adherence to antihypertensive agents among older adults covered by the public drug insurance plan in Quebec.魁北克公共药品保险计划覆盖的老年人自付费用与抗高血压药物依从性
Patient Prefer Adherence. 2017 Sep 8;11:1513-1522. doi: 10.2147/PPA.S138364. eCollection 2017.
2
Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study.向医疗服务提供者提供处方集和药品成本信息及其对药物成本和使用的影响：一项纵向非随机研究
BMC Health Serv Res. 2016 Sep 21;16(1):499. doi: 10.1186/s12913-016-1752-4.
3
Effect of electronic prescribing with formulary decision support on medication use and cost.具有处方集决策支持功能的电子处方对药物使用和成本的影响。
Arch Intern Med. 2008 Dec 8;168(22):2433-9. doi: 10.1001/archinte.168.22.2433.
4
"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada.加拿大的“突破性”药物与处方药支出增长
BMJ. 2005 Oct 8;331(7520):815-6. doi: 10.1136/bmj.38582.703866.AE. Epub 2005 Sep 2.
5
Physicians' attitudes about prescribing and knowledge of the costs of common medications.医生对常用药物处方的态度及对其成本的了解。
Arch Intern Med. 2000 Oct 9;160(18):2799-803. doi: 10.1001/archinte.160.18.2799.
6
Drug prices and third party payment: do they influence medication selection?药品价格与第三方支付：它们会影响药物选择吗？
Pharmacoeconomics. 1994 Apr;5(4):343-50. doi: 10.2165/00019053-199405040-00008.
Zotero 插件